Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Spotlight Innovation Inc. (OTC: STLT).

Full DD Report for STLT

You must become a subscriber to view this report.


Recent News from (OTC: STLT)

Spotlight Innovation Spinal Muscular Atrophy Research Collaborator Professor Kevin Hodgetts Receives $300,000 Grant from Cure SMA
URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator Professor Kevin Hodgetts has been awarded a grant of $300,000 by the nonprof...
Source: GlobeNewswire
Date: July, 24 2018 08:55
Spotlight Innovation Announces Partnership Agreement with At-Risk Youth Organization Hip-Hope
URBANDALE, IA, July 10, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that the Company has entered into a multi-year partnership agreement with Des Moines, IA-based Hip-Hope Inc., a...
Source: GlobeNewswire
Date: July, 10 2018 08:55
Article Co-authored by Spotlight Innovation Research Collaborator Describes Small Molecule Drugs with In-vivo Efficacy Against Zika Virus Infection
URBANDALE, IA, June 12, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc.  (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator and Scientific Advisory Board member Professor Hengli Tang has co-aut...
Source: GlobeNewswire
Date: June, 12 2018 08:30
Spotlight Innovation Subsidiary Celtic Biotech Iowa Announces Results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of Cancer
URBANDALE, IA, April 18, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., reported results from Cohort 1 and Cohort 2 of its Phase I ...
Source: GlobeNewswire
Date: April, 18 2018 08:48
Spotlight Innovation Subsidiary Celtic Biotech Iowa to Present Two Posters at 2018 American Association for Cancer Research (AACR) Annual Meeting
URBANDALE, IA, March 28, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., will present two posters at the American Association for Ca...
Source: GlobeNewswire
Date: March, 28 2018 09:00
Newly Issued U.S. Patent Covers Spotlight Innovation's Spinal Muscular Atrophy Drug Candidates
URBANDALE, IA, March 13, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that U.S. Patent No. 9,895,358 entitled  Combination Therapies for Treatment of Spinal Muscular Atrophy &...
Source: GlobeNewswire
Date: March, 13 2018 09:00
Venodol Roll-on, Spotlight Innovation's New Analgesic Product, Now Available at Amazon.com
URBANDALE, IA, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc.  (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Caretta Therapeutics’ new over-the-counter chronic pain relief product, V...
Source: GlobeNewswire
Date: January, 11 2018 08:30
Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product "Venodol"
URBANDALE, IA--(Marketwired - Sep 27, 2017) - Spotlight Innovation Inc. ( OTCQB : STLT ) today announced that it has formed a corporate partnership with University of Iowa Athletics that will provide ongoing radio and digital media visibility for the Venodol brand and for Venodol Roll-on ...
Source: Marketwired
Date: September, 27 2017 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.020.01380.020.012,310
2018-12-13N/A0.0105N/AN/A0
2018-12-120.0110.01050.0110.01055,900
2018-12-11N/A0.011N/AN/A0
2018-12-100.010.0110.01910.0121,636

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0733,88043,88077.2106Short
2018-12-0314,60017,60082.9545Short
2018-11-282004,7104.2463Cover
2018-11-2615,00015,10099.3377Short
2018-11-072,3002,30499.8264Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on STLT.


About Spotlight Innovation Inc. (OTC: STLT)

Logo for Spotlight Innovation Inc. (OTC: STLT)

Spotlight Innovation Inc. OTCQB: STLT acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations CROs , and contract manufacturing organizations CMOs . At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

 

 

 

Current Management

  • John M. Krohn / CEO, President, COO
  • Bill Pim / CFO, CPA, Treasurer
  • Rene Erickson / VP, Corp. Comm.
  • Sanjeev Agarwal /
  • Ralph Arthur /
  • June Beetler, D.O. /
  • John M. Krohn /
  • Craig A. Lang /

Current Share Structure

  • Market Cap: $3,776,813 - 03/16/2018
  • Authorized: 4,000,000,000 - 03/01/2018
  • Issue and Outstanding: 34,365,907 - 03/01/2018
  • Float: 9,626,903 - 02/05/2018

 


Recent Filings from (OTC: STLT)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: STLT)

Daily Technical Chart for (OTC: STLT)


Stay tuned for daily updates and more on (OTC: STLT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: STLT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in STLT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of STLT and does not buy, sell, or trade any shares of STLT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/